First approved pediatric lopinavir/ritonavir oral pellets for the treatment of AIDS in infants and young Children
Cipla Limited (Mumbai, India) announced that Co. received US FDA approval for an innovative formulation – Lopinavir/ritonavir for pediatric specific treatment for infants. According to the article, globally 3,200,000 children were living with HIV in 2013 and 240,000 children were newly infected with HIV. Although antiretroviral therapy can be life saving for these children, only 24% are currently on treatment. One third of the children born with HIV without treatment die before their first birthday and 50% die before they turn two. Detail can be found in the link:
http://www.reuters.com/article/2015/06/03/idUSFWN0YO04C20150603